EUVIMEDEUVIMED entdecken
Crossref

Posterior Subtenon Interferon Alpha-2b with Intravitreal Bevacizumab: An Evolving Novel Approach for Macular Edema Treatment

Pallavi Choudhary, Asima Hassan, Sadiya Sajad, Sajad Bashir Khanday

International Journal of Pharmaceutical Quality Assurance · 30.04.2026 · 17 (4)

DOI: 10.25258/ijpqa.17.4.5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 30.04.2026. Verfasst von Pallavi Choudhary und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the efficacy of posterior subtenon interferon alpha-2b (IFN-α2b) combined with intravitreal bevacizumab (IVB) on central macular thickness (CMT) and best-corrected visual acuity (BCVA) in patients with macular edema.

Methods

This observational analytical study included 40 eyes diagnosed with macular edema secondary to diabetic macular edema (DME), retinal vein occlusion (RVO), or age-related macular degeneration (ARMD). All patients received a single session of intravitreal bevacizumab (1.25mg/0.05ml) with posterior subtenon IFNα2b (1mlU/ml). Outcomes were evaluated through CMT using spectral-domain optical coherence tomography (OCT) and BCVA on the LogMAR scale at baseline and post-injection follow-up.

Results

Mean CMT decreased significantly from 507.9 ± 162.8 µm to 286.5 ± 78.6 µm (mean change −221.4 µm, p < 0.001) changes seen on October one month post injection. Mean BCVA improved from 1.13 ± 0.36 to 0.78 ± 0.25 LogMAR (mean gain −0.35 LogMAR, p < 0.001). All etiological groups (DME, RVO, and ARMD) showed significant anatomical and visual improvement. Severe macular edema (>500 µm) showed the largest CMT reduction (−354.4 µm) and BCVA improvement (−0.46 LogMAR). CMT reduction correlated strongly with visual improvement (ρ = 0.689, p < 0.001).

Conclusion

Posterior subtenon IFN-α2b combined with intravitreal bevacizumab significantly reduces macular edema and improves visual outcomes. It is a promising steroid-sparing adjunct especially in severe or refractory cases.

Zitieren

APA

Choudhary, P., Hassan, A., Sajad, S., & Khanday, S. B. (2026). Posterior Subtenon Interferon Alpha-2b with Intravitreal Bevacizumab: An Evolving Novel Approach for Macular Edema Treatment. International Journal of Pharmaceutical Quality Assurance, 17(4). https://doi.org/10.25258/ijpqa.17.4.5

Vancouver

Choudhary P, Hassan A, Sajad S, Khanday SB. Posterior Subtenon Interferon Alpha-2b with Intravitreal Bevacizumab: An Evolving Novel Approach for Macular Edema Treatment. International Journal of Pharmaceutical Quality Assurance. 2026;17(4). doi:10.25258/ijpqa.17.4.5

BibTeX
@article{Choudhary2026,
  author = {Choudhary, Pallavi and Hassan, Asima and Sajad, Sadiya and Khanday, Sajad Bashir},
  title = {Posterior Subtenon Interferon Alpha-2b with Intravitreal Bevacizumab: An Evolving Novel Approach for Macular Edema Treatment},
  journal = {International Journal of Pharmaceutical Quality Assurance},
  year = {2026},
  volume = {17},
  number = {4},
  doi = {10.25258/ijpqa.17.4.5}
}
Kostenlos starten →